Alnylam Pharmaceuticals faces a significant drop in stock value amidst growing concerns in the biotechnology sector.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) saw its stock price decline by 1.51% today, closing at CA$247.85. This drop comes as the company navigates a challenging environment in the biotech industry, particularly in light of recent market developments and competitive pressures.
Investor takeaway: Investors should be cautious as Alnylam's recent performance reflects broader challenges in the biotech sector, especially in the Alzheimer's treatment space, where competition is intensifying and regulatory scrutiny remains high.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$32.69B
P/E
42.5x
52W high
$495.55
52W low
$197.81
1W change
+5.62%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Sep 17, 2026
Wall Street analysts forecast ALNY stock price to rise 47.6% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.35
+47.6% Upside
Current Price
C$251.65
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
45.3%
Annualized
90-Day Vol
79.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$210.50
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$237.11 | C$202.78 – C$277.25 |
| 60 trading days | C$223.41 | C$179.08 – C$278.71 |
| 90 trading days | C$210.50 | C$160.55 – C$275.99 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.51% Decline in Stock Price
Alnylam's stock performance shows investor concerns about its competitive position and the broader challenges facing the biotech industry.
Bull case
Alnylam is making strides with innovative RNAi therapies that could change how we treat Alzheimer's and other diseases. If their clinical trials succeed, the company is well-positioned for long-term growth.
Bear case
The competition in Alzheimer's drug development is tough, with established players like Biogen making significant progress. This could overshadow Alnylam's efforts and lead to a loss of market share.
Advertisement
Market Reaction to Competitive Pressures
Alnylam's stock decline today reflects growing investor worries about competitive pressures in the Alzheimer's drug market. With established players like Biogen advancing, Alnylam's position could be at risk as it works to establish its RNAi therapies in a crowded field.
Regulatory Challenges and Development Risks
The biotechnology sector, especially in rare diseases and Alzheimer's treatment, faces strict regulatory scrutiny. Alnylam must navigate these challenges while ensuring its clinical trials produce positive results. Any setbacks in trial outcomes or regulatory approvals could further impact investor sentiment and stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
